Peripheral Neuropathy Trial, Recruiting (NCT07565844)

Peripheral Neuropathy Trial, Recruiting NCT07565844 Sponsor: Zagazig University Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT07565844 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have had shingles and are still experiencing persistent nerve pain along the same area of skin for at least 90 days after the shingles outbreak
People aged 18 years or older, of any gender
People who are willing to follow the study procedures and attend all required follow-up appointments
People who are able and willing to sign a written consent form agreeing to take part

Who may not be able to join:

People who have had an allergic reaction to any of the treatments being used in this study
People who are pregnant
People who have any type of skin infection in the area affected by their shingles pain
People whose immune system is weakened, including those with cancer or HIV
People who have a condition called bone marrow aplasia, which affects the body's ability to produce blood cells
People who have a known tendency to bleed easily, problems with how their blood clots, or a low platelet count (below a certain level in a blood test)
People who regularly take blood-thinning or anti-clotting medications

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +201067070550

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07565844

Sponsor: Zagazig University

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: +201067070550

More information: https://clinicaltrials.gov/study/NCT07565844

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have had shingles and are still experiencing persistent nerve pain along the same area of skin for at least 90 days after the shingles outbreak
People aged 18 years or older, of any gender
People who are willing to follow the study procedures and attend all required follow-up appointments
People who are able and willing to sign a written consent form agreeing to take part

Who may not be able to join:

People who have had an allergic reaction to any of the treatments being used in this study
People who are pregnant
People who have any type of skin infection in the area affected by their shingles pain
People whose immune system is weakened, including those with cancer or HIV
People who have a condition called bone marrow aplasia, which affects the body's ability to produce blood cells
People who have a known tendency to bleed easily, problems with how their blood clots, or a low platelet count (below a certain level in a blood test)
People who regularly take blood-thinning or anti-clotting medications

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Zagazig University

Registry

ClinicalTrials.gov

Start date

2 February 2025

Est. completion

6 August 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in Pain Severity Using the Visual Analog Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov